193 related articles for article (PubMed ID: 38473207)
21. Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role.
Lloyd MR; Wander SA; Hamilton E; Razavi P; Bardia A
Ther Adv Med Oncol; 2022; 14():17588359221113694. PubMed ID: 35923930
[TBL] [Abstract][Full Text] [Related]
22. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer.
Fleming FJ; Hill AD; McDermott EW; O'Higgins NJ; Young LS
J Clin Endocrinol Metab; 2004 Jan; 89(1):375-83. PubMed ID: 14715875
[TBL] [Abstract][Full Text] [Related]
23. Transcriptional activation of breast cancer-associated gene 2 by estrogen receptor.
Kona FR; Stark K; Bisoski L; Buac D; Cui Q; Dou QP
Breast Cancer Res Treat; 2012 Sep; 135(2):495-503. PubMed ID: 22850893
[TBL] [Abstract][Full Text] [Related]
24. Expression of human estrogen receptor using an efficient adenoviral gene delivery system is able to restore hormone-dependent features to estrogen receptor-negative breast carcinoma cells.
Lazennec G; Katzenellenbogen BS
Mol Cell Endocrinol; 1999 Mar; 149(1-2):93-105. PubMed ID: 10375022
[TBL] [Abstract][Full Text] [Related]
25. E3 ubiquitin ligase Trim33 ubiquitylates Annexin A2 to promote NF-κB induced skin inflammation in psoriasis.
Zhang J; Zhu J; Chen X; Xia H; Yang L
J Dermatol Sci; 2022 Sep; 107(3):160-168. PubMed ID: 36096861
[TBL] [Abstract][Full Text] [Related]
26. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.
Yamashita H; Nishio M; Kobayashi S; Ando Y; Sugiura H; Zhang Z; Hamaguchi M; Mita K; Fujii Y; Iwase H
Breast Cancer Res; 2005; 7(5):R753-64. PubMed ID: 16168121
[TBL] [Abstract][Full Text] [Related]
27. High estrogen receptor alpha activation confers resistance to estrogen deprivation and is required for therapeutic response to estrogen in breast cancer.
Traphagen NA; Hosford SR; Jiang A; Marotti JD; Brauer BL; Demidenko E; Miller TW
Oncogene; 2021 May; 40(19):3408-3421. PubMed ID: 33875787
[TBL] [Abstract][Full Text] [Related]
28. Tripartite motif-containing 3 (TRIM3) enhances ER signaling and confers tamoxifen resistance in breast cancer.
Ye R; AiErken N; Kuang X; Zeng H; Shao N; Lin Y; Liu P; Wang S
Oncogenesis; 2021 Sep; 10(9):60. PubMed ID: 34508066
[TBL] [Abstract][Full Text] [Related]
29. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
[TBL] [Abstract][Full Text] [Related]
30. Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis.
Zou Y; Tsai WB; Cheng CJ; Hsu C; Chung YM; Li PC; Lin SH; Hu MC
Breast Cancer Res; 2008; 10(1):R21. PubMed ID: 18312651
[TBL] [Abstract][Full Text] [Related]
31. Estrogen response element-dependent regulation of transcriptional activation of estrogen receptors alpha and beta by coactivators and corepressors.
Klinge CM; Jernigan SC; Mattingly KA; Risinger KE; Zhang J
J Mol Endocrinol; 2004 Oct; 33(2):387-410. PubMed ID: 15525597
[TBL] [Abstract][Full Text] [Related]
32. Differential effects of estrogen-dependent transactivation vs. transrepression by the estrogen receptor on invasiveness of HER2 overexpressing breast cancer cells.
Patki M; Salazar Md; Trumbly R; Ratnam M
Biochem Biophys Res Commun; 2015 Feb; 457(3):404-11. PubMed ID: 25582774
[TBL] [Abstract][Full Text] [Related]
33. Estrogen receptor beta binds Sp1 and recruits a corepressor complex to the estrogen receptor alpha gene promoter.
Bartella V; Rizza P; Barone I; Zito D; Giordano F; Giordano C; Catalano S; Mauro L; Sisci D; Panno ML; Fuqua SA; Andò S
Breast Cancer Res Treat; 2012 Jul; 134(2):569-81. PubMed ID: 22622808
[TBL] [Abstract][Full Text] [Related]
34. FGF1 supports glycolytic metabolism through the estrogen receptor in endocrine-resistant and obesity-associated breast cancer.
Castillo-Castrejon M; Sankofi BM; Murguia SJ; Udeme AA; Cen HH; Xia YH; Thomas NS; Berry WL; Jones KL; Richard VR; Zahedi RP; Borchers CH; Johnson JD; Wellberg EA
Breast Cancer Res; 2023 Aug; 25(1):99. PubMed ID: 37608351
[TBL] [Abstract][Full Text] [Related]
35. Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes.
Daniel AR; Gaviglio AL; Knutson TP; Ostrander JH; D'Assoro AB; Ravindranathan P; Peng Y; Raj GV; Yee D; Lange CA
Oncogene; 2015 Jan; 34(4):506-15. PubMed ID: 24469035
[TBL] [Abstract][Full Text] [Related]
36. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.
Kim C; Tang G; Pogue-Geile KL; Costantino JP; Baehner FL; Baker J; Cronin MT; Watson D; Shak S; Bohn OL; Fumagalli D; Taniyama Y; Lee A; Reilly ML; Vogel VG; McCaskill-Stevens W; Ford LG; Geyer CE; Wickerham DL; Wolmark N; Paik S
J Clin Oncol; 2011 Nov; 29(31):4160-7. PubMed ID: 21947828
[TBL] [Abstract][Full Text] [Related]
37. Characterization of a membrane-associated estrogen receptor in breast cancer cells and its contribution to hormone therapy resistance using a novel selective ligand.
Niwa T; Takanobu J; Suzuki K; Sato Y; Yamaguchi Y; Hayashi SI
J Steroid Biochem Mol Biol; 2020 Jul; 201():105671. PubMed ID: 32289430
[TBL] [Abstract][Full Text] [Related]
38. Endocrine therapy--current benefits and limitations.
Nicholson RI; Johnston SR
Breast Cancer Res Treat; 2005; 93 Suppl 1():S3-10. PubMed ID: 16247594
[TBL] [Abstract][Full Text] [Related]
39. ESR1 fusions and therapeutic resistance in metastatic breast cancer.
Nagy Z; Jeselsohn R
Front Oncol; 2022; 12():1037531. PubMed ID: 36686845
[TBL] [Abstract][Full Text] [Related]
40. Estradiol as a Targeted, Late-Line Therapy in Metastatic Breast Cancer with Estrogen Receptor Amplification.
Kota K; Brufsky A; Oesterreich S; Lee A
Cureus; 2017 Jul; 9(7):e1434. PubMed ID: 28924522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
